Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) FCF Margin (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed FCF Margin for 8 consecutive years, with 164.32% as the latest value for Q1 2022.

  • Quarterly FCF Margin rose 15352.0% to 164.32% in Q1 2022 from the year-ago period, while the trailing twelve-month figure was 675.21% through Dec 2022, down 49304.0% year-over-year, with the annual reading at 676.01% for FY2022, 49384.0% down from the prior year.
  • FCF Margin hit 164.32% in Q1 2022 for Aptevo Therapeutics, down from 109.09% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 56.47% in Q4 2019 to a low of 979.49% in Q2 2020.
  • Historically, FCF Margin has averaged 328.52% across 5 years, with a median of 215.91% in 2019.
  • Biggest five-year swings in FCF Margin: plummeted -76358bps in 2020 and later skyrocketed 80444bps in 2021.
  • Year by year, FCF Margin stood at 773.64% in 2018, then skyrocketed by 93bps to 56.47% in 2019, then plummeted by -357bps to 258.03% in 2020, then surged by 58bps to 109.09% in 2021, then tumbled by -51bps to 164.32% in 2022.
  • Business Quant data shows FCF Margin for APVO at 164.32% in Q1 2022, 109.09% in Q4 2021, and 169.74% in Q3 2021.